{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T21:48:52Z","timestamp":1773352132621,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008387","name":"Xi'an Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jad.2025.120473","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:05:51Z","timestamp":1760501151000},"page":"120473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"PB","title":["Development of a nomogram risk prediction model for subtherapeutic valproic acid plasma concentration: A retrospective cohort study"],"prefix":"10.1016","volume":"393","author":[{"given":"Jing","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suo","family":"zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jad.2025.120473_bb0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4103\/jpbs.JPBS_368_19","article-title":"A retrospective study on therapeutic drug monitoring of mood stabilizers in real-life clinical scenario","volume":"12","author":"Abu-Qurain","year":"2020","journal-title":"J. Pharm. Bioallied Sci."},{"issue":"2","key":"10.1016\/j.jad.2025.120473_bb0010","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1176\/appi.ajp.163.2.272","article-title":"Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania","volume":"163","author":"Allen","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2025.120473_bb0015","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s11096-019-00864-w","article-title":"Estimation of apparent clearance of valproic acid in adult Saudi patients","volume":"41","author":"Alqahtani","year":"2019","journal-title":"Int. J. Clin. Pharm."},{"issue":"9","key":"10.1016\/j.jad.2025.120473_bb0020","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00213-024-06603-y","article-title":"Predictors of valproic acid steady-state serum levels in adult and pediatric psychiatric inpatients: a comparative analysis","volume":"241","author":"Avrahami","year":"2024","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.jad.2025.120473_bb0025","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clpt.2004.08.021","article-title":"Bioequivalence revisited: influence of age and sex on CYP enzymes","volume":"76","author":"Bebia","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2025.120473_bb0030","series-title":"Design and Optimization of Dosage Regimens; Pharmacokinetic Data","author":"Benet","year":"1985"},{"issue":"6","key":"10.1016\/j.jad.2025.120473_bb0035","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/ajp.153.6.765","article-title":"Relation of serum valproate concentration to response in mania","volume":"153","author":"Bowden","year":"1996","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.120473_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ph15010105","article-title":"A 5-year study of lithium and valproic acid drug monitoring in patients with bipolar disorders in an italian clinical center","volume":"15","author":"Carli","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jad.2025.120473_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101678","article-title":"Comparative effectiveness of valproic acid in different serum concentrations for maintenance treatment of bipolar disorder: a retrospective cohort study using target trial emulation framework","volume":"54","author":"Chen","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jad.2025.120473_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2023.103613","article-title":"Clinical use of mood stabilizers beyond treatment for bipolar disorder: the REAP-MS study","volume":"85","author":"Chen","year":"2023","journal-title":"Asian J. Psychiatr."},{"issue":"10","key":"10.1016\/j.jad.2025.120473_bb0055","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00228-012-1277-7","article-title":"Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"68","author":"Chu","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2025.120473_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2024.100771","article-title":"A clinical nomogram for predicting substandard serum Valproic acid concentrations in Chinese patients with epilepsy","volume":"102","author":"Duan","year":"2025","journal-title":"Curr. Ther. Res. Clin. Exp."},{"issue":"6","key":"10.1016\/j.jad.2025.120473_bb0065","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/01.WNF.0000228209.69524.E8","article-title":"Therapeutic monitoring of valproate in psychiatry: how far have we progressed?","volume":"29","author":"Fleming","year":"2006","journal-title":"Clin. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.jad.2025.120473_bb0070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2710.1995.tb00651.x","article-title":"Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy","volume":"20","author":"Gidal","year":"1995","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.jad.2025.120473_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073591","article-title":"Diagnosis and management of bipolar disorders","volume":"381","author":"Goes","year":"2023","journal-title":"Bmj"},{"key":"10.1016\/j.jad.2025.120473_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115281","article-title":"Pharmacokinetics of obese adults: not only an increase in weight","volume":"166","author":"Gouju","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1\u221202","key":"10.1016\/j.jad.2025.120473_bb0085","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.jad.2025.120473_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092573","article-title":"Off-label use of sodium valproate for schizophrenia","volume":"9","author":"Horowitz","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2025.120473_bb0095","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jad.2023.11.047","article-title":"Valproic acid monitoring: serum prediction using a machine learning framework from multicenter real-world data","volume":"347","author":"Hsu","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"11","key":"10.1016\/j.jad.2025.120473_bb0100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2165\/00003088-200544110-00005","article-title":"The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics","volume":"44","author":"Ishizawa","year":"2005","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.jad.2025.120473_bb0105","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2165\/00003088-199733040-00005","article-title":"Clinical pharmacokinetic considerations in the elderly. An update","volume":"33","author":"Kinirons","year":"1997","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.jad.2025.120473_bb0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/03602530902722679","article-title":"Pharmacokinetics and drug metabolism in the elderly","volume":"41","author":"Klotz","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.jad.2025.120473_bb0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpsychires.2025.03.045","article-title":"Anti-suicidal effectiveness of clozapine, lithium, and valproate in patients with schizophrenia and bipolar disorder: a real-world nationwide study","volume":"185","author":"Lee","year":"2025","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.jad.2025.120473_bb0120","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/FTD.0000000000000100","article-title":"Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen","volume":"37","author":"Lin","year":"2015","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.jad.2025.120473_bb0125","article-title":"Valproate for acute mood episodes in bipolar disorder","author":"Macritchie","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.jad.2025.120473_bb0130","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2011.12","article-title":"Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative","volume":"68","author":"Merikangas","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2025.120473_bb0135","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.clinthera.2017.04.005","article-title":"Population pharmacokinetics of valproic acid in patients with mania: implication for individualized dosing regimens","volume":"39","author":"Methaneethorn","year":"2017","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.jad.2025.120473_bb0140","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1017\/S1092852920001285","article-title":"Valproate for schizophrenia: ambrosia?","volume":"26","author":"Naguy","year":"2021","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2025.120473_bb0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.seizure.2018.04.012","article-title":"Determinants of free serum valproate concentration: a prospective study in patients on divalproex sodium monotherapy","volume":"59","author":"Nasreddine","year":"2018","journal-title":"Seizure"},{"issue":"14","key":"10.1016\/j.jad.2025.120473_bb0150","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1001\/jama.2023.18588","article-title":"Diagnosis and treatment of bipolar disorder: a review","volume":"330","author":"Nierenberg","year":"2023","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.jad.2025.120473_bb0155","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1528-1157.1979.tb04841.x","article-title":"Linear relationship between plasma concentration and dosage of sodium valproate","volume":"20","author":"Nutt","year":"1979","journal-title":"Epilepsia"},{"key":"10.1016\/j.jad.2025.120473_bb0160","article-title":"Bipolar disorders: an update on critical aspects","volume":"48","author":"Oliva","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"issue":"6","key":"10.1016\/j.jad.2025.120473_bb0165","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2125.1984.tb02401.x","article-title":"Pharmacokinetics of valproic acid in the elderly","volume":"17","author":"Perucca","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jad.2025.120473_bb0170","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/acps.13498","article-title":"Real-world effectiveness of mood stabilizer use in schizophrenia","volume":"147","author":"Puranen","year":"2023","journal-title":"Acta Psychiatr. Scand."},{"issue":"5","key":"10.1016\/j.jad.2025.120473_bb0175","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/FTD.0000000000001199","article-title":"Retrospective analysis of steady-state sodium valproate plasma concentrations in Chinese patients with bipolar disorder: impact of demographic and clinical characteristics","volume":"46","author":"Qiming","year":"2024","journal-title":"Ther. Drug Monit."},{"issue":"5","key":"10.1016\/j.jad.2025.120473_bb0180","first-page":"452","article-title":"Drug development and use in the elderly: search for the right dose and dosing regimen (parts I and II)","volume":"58","author":"Shah","year":"2004"},{"issue":"9","key":"10.1016\/j.jad.2025.120473_bb0185","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00228-016-2087-0","article-title":"Impact of age, gender and CYP2C9\/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data","volume":"72","author":"Smith","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.jad.2025.120473_bb0190","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/ejhpharm-2020-002367","article-title":"Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy","volume":"29","author":"Song","year":"2022","journal-title":"Eur. J. Hosp. Pharm."},{"issue":"3","key":"10.1016\/j.jad.2025.120473_bb0195","doi-asserted-by":"crossref","first-page":"305","DOI":"10.31887\/DCNS.2010.12.3\/sstilo","article-title":"The epidemiology of schizophrenia: replacing dogma with knowledge","volume":"12","author":"Stilo","year":"2010","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jad.2025.120473_bb0200","first-page":"225","article-title":"Evaluation of CYP2C19 genetic variant and its lack of association with valproic acid plasma concentrations among Zhuang and Han schizophrenia patients in Guangxi","volume":"17","author":"Teng","year":"2024","journal-title":"Pharmgenomics Pers. Med."},{"issue":"5","key":"10.1016\/j.jad.2025.120473_bb0205","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00007691-199210000-00013","article-title":"Relationship between serum concentration and dose of valproic acid during monotherapy in adult outpatients","volume":"14","author":"Tisdale","year":"1992","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jad.2025.120473_bb0210","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12888-015-0559-x","article-title":"Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia","volume":"15","author":"Tracy","year":"2015","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.120473_bb0215","doi-asserted-by":"crossref","first-page":"23150","DOI":"10.1038\/s41598-021-02628-x","article-title":"Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia","volume":"11","author":"Wang","year":"2021","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jad.2025.120473_bb0220","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"issue":"12","key":"10.1016\/j.jad.2025.120473_bb0225","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/j.1552-4604.1997.tb04301.x","article-title":"Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics","volume":"37","author":"Yukawa","year":"1997","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.jad.2025.120473_bb0230","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/17512433.2022.2075849","article-title":"Published population pharmacokinetic models of valproic acid in adult patients: a systematic review and external validation in a Chinese sample of inpatients with bipolar disorder","volume":"15","author":"Zang","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jad.2025.120473_bb0235","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00228-021-03246-2","article-title":"Population pharmacokinetics of valproic acid in adult Chinese patients with bipolar disorder","volume":"78","author":"Zang","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.jad.2025.120473_bb0240","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.4088\/JCP.16r10782","article-title":"Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials","volume":"78","author":"Zheng","year":"2017","journal-title":"J. Clin. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725019159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725019159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:07:37Z","timestamp":1773313657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725019159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":48,"alternative-id":["S0165032725019159"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.120473","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a nomogram risk prediction model for subtherapeutic valproic acid plasma concentration: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.120473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120473"}}